Overview

A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia

Status:
RECRUITING
Trial end date:
2028-08-22
Target enrollment:
Participant gender:
Summary
To look at the safety and effectiveness of emapalumab for the treatment of prolonged severe cytopenia in participants with LBCL who receive CART.
Phase:
PHASE2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Sobi, Inc.
Treatments:
Emapalumab